EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Medexus Pharmaceuticals Inc (MDP) fair value: what the stock is really worth

As of Sep 28, 2026: fair value of Medexus Pharmaceuticals Inc C$3.73, price C$5.12, upside -27.1%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CA · ISIN CA58410Q2036

MP Some data Sep 27, 2026

Medexus Pharmaceuticals Inc

MDP · TO

Weak valuationQuality is weak on top of the rich price.

!Fair value C$3.73 · Overvalued (−27.1%)
!Quality 25/100
!Weak Growth (revenue 5y +4.5 %/yr)
!Loss-making · -2.4% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (2/11)
!Narrow moat 24/100
!Evidence only medium, so the estimate is less certain
Watch Medexus Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$7.75 C$0.8900 Fair Value C$3.73 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range C$0.8900 – C$7.75 · fair‑value band C$2.39 – C$6.07 · the C$5.12 price screens above the C$3.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Medexus Pharmaceuticals in your weekly email

Every Wednesday you see whether Medexus Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.

Show more

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Stock analysis

Medexus Pharmaceuticals Inc (MDP) currently trades at C$5.12, while our model-based Fair Value estimate is C$3.73, implying the stock looks roughly 37.2% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of C$5.89 per share, and 7 of the 13 models we run sit above the C$5.12 price.

Bear case: the Earnings-Based group reads lowest at C$1.28, and 6 of the 13 models stay below the price. Evidence for this calculation is medium.

Scenario range: C$2.39 (bear) to C$6.07 (bull), the price of C$5.12 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Medexus Pharmaceuticals Inc reported revenue of $99.3M in FY2026 versus $76.7M in FY2022, a compound +6.7%/yr. Reported net income was −$2.4M in FY2026.

Key figures

Market cap C$165M (≈ $117M) · P/S ratio 1.62 · EPS (TTM) C$−0.1000 · Net margin −2.4% · Return on equity −4.7% · Return on assets (EBIT) 2.3% · Operating margin 6.7% · Revenue (TTM) $99.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 100% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −27%, MDP screens richer than that median.

Fair Value models

Bear C$2.39 Fair Value C$3.73 Bull C$6.07
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF C$3.85 C$5.64 C$10.87 75
EPV C$1.07 C$1.28 C$1.44 74
Growth DCF C$3.57 C$5.94 C$10.15 74
All 13 models by family
DCF Models
FCF DCF C$3.85 C$5.64 C$10.87 75
5Y Revenue Exit C$2.56 C$4.57 C$8.62 67
5Y EBITDA Exit C$5.57 C$10.80 C$20.78 69
10Y Revenue Exit C$2.90 C$5.89 C$8.05 64
10Y EBITDA Exit C$4.83 C$11.16 C$22.98 61
Earnings-Based
EPV C$1.07 C$1.28 C$1.44 74
Multiples
EV/EBIT C$2.73 C$3.84 C$4.95 65
EV/EBITDA C$6.72 C$9.16 C$11.60 67
EV/Revenue C$1.77 C$2.79 C$3.81 53
Asset-Based
NCAV (Graham) C$1.10 C$1.47 C$2.19 54
Growth DCF
Growth DCF C$3.57 C$5.94 C$10.15 74
Rev-Margin DCF C$2.56 C$5.32 C$9.65 67
Economic Profit
ROIC Compounder C$1.07 C$1.28 C$1.44 70

Open the full fair value analysis →

Notify me when MDP reaches fair value

Put MDP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 28 · Market factors (momentum, volatility) 72

Profitability 26
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 30
Balance sheet, leverage, solvency risk
Investment 42
Disciplined investing over empire-building
Low Volatility 21
Calm price path (market factor)
Momentum 93
Price trend over the last 3–12 months (market factor)
52W Momentum 94
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Start year 2021 (pandemic). Over 10 years: +42.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.7% (2021) → 5.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+26.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +30.4% a year for the price and +23.6% for the forecasts.
Forecast 2027 (sales)+61.1%
Forecast 2028 (sales)+23.1%
Projected 2029 (sales)+20.4%
Projected 2030 (sales)+17.8%
Projected 2031 (sales)+15.2%

MDP screens 37% overvalued. Compare with Merck KGaA →

Compare Medexus Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 627 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −27.1% · Below median
Profitability
Return on assets 2.3% · Below median
Net margin (TTM) −2.4% · Below median
Operating margin (TTM) 6.7% · Below median
Growth and dividend
Revenue growth −0.4% · Below median
Balance sheet
Debt / equity 0.41× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.38× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 1.18× · Cheaper than median
P/FCF 31.4× · Pricier than median
EV/EBITDA 8.5× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 17
PAST (return on equity)0 · sector 26
HEALTH (low debt)80 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €135.00 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.86 $11.40 −40%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $71.05 $110.50 +56%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medexus Pharmaceuticals Inc · Fair Value
C$3.73 −37%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Medexus Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/MDP

Frequently asked questions

Is Medexus Pharmaceuticals Inc (MDP) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of C$3.73 versus a price of C$5.12, about −27% upside (overvalued).
What is the fair value of MDP?
Our model-based fair value for Medexus Pharmaceuticals Inc is C$3.73 (as of Sep 27, 2026), built from audited fundamentals. The current price: C$5.12.
What is the quality score of MDP?
Medexus Pharmaceuticals Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medexus Pharmaceuticals Inc (MDP)?
Our model-based price target is the fair value of C$3.73 (as of Sep 27, 2026) from 13 valuation models. Cautious scenario C$2.39, optimistic scenario C$6.07. It is a calculation from audited fundamentals, not an analyst target.
What is the Medexus Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at C$3.73, about −27% upside versus a price of C$5.12 (overvalued). Cautious scenario C$2.39, optimistic scenario C$6.07. The calculation is refreshed regularly with new filings.
What is the revenue of Medexus Pharmaceuticals Inc (MDP)?
Medexus Pharmaceuticals Inc reported trailing-twelve-month revenue of about $99.3M (latest available figure, as of Sep 27, 2026).
What growth is priced into Medexus Pharmaceuticals Inc (MDP)?
For today's price to be fair in a discounted-cash-flow model, Medexus Pharmaceuticals Inc would have to grow free cash flow by +33.5 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of MDP use?
Our models discount Medexus Pharmaceuticals Inc at 15.0 %: a base by market capitalisation (micro), damped by beta 1.81, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medexus Pharmaceuticals Inc that is +33.5 % per year a year over ten years, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Medexus Pharmaceuticals Inc (MDP) delivered so far?
Over the past 5 years revenue at Medexus Pharmaceuticals Inc grew +4.5 % a year. The price currently implies +33.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medexus Pharmaceuticals Inc (MDP) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Medexus Pharmaceuticals Inc (+33.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medexus Pharmaceuticals Inc (MDP)?
The free-cash-flow yield on the price is 3.19 %: that much free cash flow Medexus Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medexus Pharmaceuticals Inc (MDP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medexus Pharmaceuticals Inc it is C$3.73 per share (as of Sep 27, 2026), against a price of C$5.12. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Medexus Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, MDP trades above its calculated fair value: price C$5.12, fair value C$3.73, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDP?
No. The price is what the market pays today (C$5.12); the fair value is what the company's own numbers justify (C$3.73). For Medexus Pharmaceuticals Inc the two are C$1.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medexus Pharmaceuticals Inc worth?
The market values Medexus Pharmaceuticals Inc at about C$165M (market capitalisation, as of Sep 27, 2026). Per share that is C$5.12; our models calculate a fair value of C$3.73 per share.
What do the bullish and bearish scenarios say about MDP?
Our models span a range for Medexus Pharmaceuticals Inc: cautious scenario C$2.39, base C$3.73, optimistic C$6.07 per share (as of Sep 27, 2026, price C$5.12). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medexus Pharmaceuticals Inc (MDP)?
Balance-sheet figures for Medexus Pharmaceuticals Inc (as of Sep 27, 2026): return on equity −4.7%, debt of 0.41 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is MDP from its 52-week high?
Medexus Pharmaceuticals Inc trades at C$5.12, about 6% below its 52-week high of C$5.45 and 100% above the low of C$2.56 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of C$3.73 is for.
Which stocks are comparable to Medexus Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medexus Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 27, 2026: price C$5.12, calculated fair value C$3.73 (−27%), Quality Score 25/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDP calculated?
We run Medexus Pharmaceuticals Inc through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$3.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. Medexus Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medexus Pharmaceuticals Inc (MDP)?
The closing price on Sep 28, 2026 was C$5.12. Our model-based fair value is C$3.73, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medexus Pharmaceuticals Inc right now?
Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (C$2.39 to C$6.07) leaves room in how you read the outcome.

Key figures of Medexus Pharmaceuticals Inc

How large is the market capitalisation of Medexus Pharmaceuticals Inc (MDP)?
The market capitalisation of Medexus Pharmaceuticals Inc is C$165M (≈ $117M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medexus Pharmaceuticals Inc (MDP)?
The price-to-sales ratio of Medexus Pharmaceuticals Inc is 1.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medexus Pharmaceuticals Inc (MDP)?
Earnings per share at Medexus Pharmaceuticals Inc are C$−0.1000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medexus Pharmaceuticals Inc (MDP)?
The net margin of Medexus Pharmaceuticals Inc is −2.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medexus Pharmaceuticals Inc (MDP)?
The return on equity (ROE) of Medexus Pharmaceuticals Inc is −4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medexus Pharmaceuticals Inc (MDP)?
On an EBIT basis the return on assets of Medexus Pharmaceuticals Inc is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medexus Pharmaceuticals Inc (MDP)?
The operating margin of Medexus Pharmaceuticals Inc is 6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medexus Pharmaceuticals Inc (MDP)?
Revenue at Medexus Pharmaceuticals Inc is growing −0.4% versus a year earlier (3y avg −2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medexus Pharmaceuticals Inc (MDP)?
Earnings per share at Medexus Pharmaceuticals Inc are growing −91.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medexus Pharmaceuticals Inc (MDP) carry?
The net debt of Medexus Pharmaceuticals Inc is $15.7M (fiscal year 2026, ≈ 4.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medexus Pharmaceuticals Inc in the live analysis

One click puts Medexus Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.